Eliot Brinton, MD, opens a discussion surrounding the treatment landscape for patients with homozygous familial hypercholesterolemia (HoFH).
Eliot Brinton, MD: I’m Dr Elliot Brinton. I’m the president of the Utah Lipid Center in Salt Lake City, Utah. We’re the only LDL [low-density lipoprotein] apheresis center between Denver and the West Coast, which tells you we don’t have enough apheresis centers if I have to cover parts of 7 states. But it’s a pleasure to be here to talk about homozygous FH [familial hypercholesterolemia]. Homozygous familial hypercholesterolemia [HoFH] is a very important genetic disorder. I’ve been looking at it for 4 decades. In recent years I served as president of the American Board of Clinical Lipidology. There’s board certification for clinical lipidology, and it was my privilege to help guide that for a couple of years.
Homozygous FH is the rare cousin of heterozygous FH. Heterozygous FH is the most common and clinically important monogenic disorder in the world. It’s quite common—1 of 100 individuals have this. Homozygous FH is much more rare. It occurs in 4 per 1 million. It’s even in its distribution around the world, except for certain hot spots. Several populations are known to have a high prevalence of heterozygous and homozygous FH: French Canadians, South African Afrikaners, and Lebanese Christians, are some of the populations known for this. With those exceptions, it’s around 3 or 4 per 1 million worldwide, with genetic hot spots that have to do with the founder effect.
It’s not common, but it occurs around the world. It’s independent of race and sex. Cholesterol tends to go up with age, but homozygous FH presents very early in childhood. That’s a key factor about HoFH. We’re not dealing with a typical middle-aged or older patient with high cholesterol. We’re focusing on starting diagnosis and treatment as young as possible.
Transcript edited for clarity.